Medicamen Organics Ltd
Incorporated in 1995, Medicamen Organics Ltd develops, manufactures, and distributes a broad range of pharmaceutical dosages including generic dosage[1]
- Market Cap ₹ 27.9 Cr.
- Current Price ₹ 22.9
- High / Low ₹ 48.8 / 19.1
- Stock P/E
- Book Value ₹ 23.6
- Dividend Yield 0.00 %
- ROCE -10.7 %
- ROE -13.7 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.97 times its book value
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of 3.01% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 300 days.
- Working capital days have increased from 144 days to 223 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 25.27 | 38.19 | 22.63 | |
| 20.53 | 31.58 | 26.38 | |
| Operating Profit | 4.74 | 6.61 | -3.75 |
| OPM % | 18.76% | 17.31% | -16.57% |
| 1.07 | 0.10 | 0.08 | |
| Interest | 0.65 | 0.54 | 0.71 |
| Depreciation | 0.72 | 0.74 | 0.90 |
| Profit before tax | 4.44 | 5.43 | -5.28 |
| Tax % | 40.77% | 25.41% | -23.86% |
| 2.62 | 4.05 | -4.02 | |
| EPS in Rs | 3.05 | 3.46 | -3.30 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -41% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -199% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -52% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 3% |
| Last Year: | -14% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 8.60 | 11.70 | 12.17 |
| Reserves | 6.66 | 18.43 | 16.56 |
| 12.66 | 12.35 | 14.30 | |
| 10.52 | 16.73 | 8.60 | |
| Total Liabilities | 38.44 | 59.21 | 51.63 |
| 10.35 | 10.13 | 13.37 | |
| CWIP | 0.15 | 2.22 | 0.09 |
| Investments | 0.00 | 0.00 | 0.00 |
| 27.94 | 46.86 | 38.17 | |
| Total Assets | 38.44 | 59.21 | 51.63 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| -3.66 | -4.54 | -4.60 | |
| -0.34 | -2.35 | -1.72 | |
| 4.01 | 10.47 | 3.48 | |
| Net Cash Flow | 0.01 | 3.58 | -2.83 |
| Free Cash Flow | -4.01 | -6.99 | -6.34 |
| CFO/OP | -73% | -67% | 119% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 241.21 | 247.06 | 300.32 |
| Inventory Days | 244.39 | 228.39 | 243.18 |
| Days Payable | 281.81 | 356.77 | 128.52 |
| Cash Conversion Cycle | 203.80 | 118.69 | 414.98 |
| Working Capital Days | 74.24 | 135.14 | 222.74 |
| ROCE % | 16.88% | -10.66% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Tablets Sales Contribution % ・Includes some standalone data |
|
|||
| Installed Capacity - Capsules Lakh capsules per annum ・Standalone data |
||||
| Installed Capacity - Dry Powder Sachets Units per annum ・Standalone data |
||||
| Installed Capacity - Ointment Kg per annum ・Standalone data |
||||
| Installed Capacity - Suspension/Oral Liquids Liters per annum ・Standalone data |
||||
| Installed Capacity - Tablets Lakh tablets per annum ・Standalone data |
||||
| Geographic Presence (Countries) Number |
||||
| Capacity Utilization (Average) % ・Standalone data |
||||
| Order Book - Povidone Iodine Solution Units ・Standalone data |
||||
| Total Product SKUs Number |
||||
Extracted by Screener AI
Documents
Announcements
-
General Updates
9 June 2026 - Auditor certified ₹12.29 crore preferential allotment of 39 lakh shares and warrants on June 9, 2026.
-
Committee Meeting Updates
9 June 2026 - Allotted 27.14 lakh shares and 11.86 lakh warrants for ₹13.65 crore on June 9, 2026.
-
Disclosure under SEBI Takeover Regulations
3 June 2026 - Ritu Gupta has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
-
Disclosure under SEBI Takeover Regulations
3 June 2026 - Bal Kishan Gupta has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) and 31 (5) of the SEBI (Substantial Acquisition of Shares …
-
Disclosure under SEBI Takeover Regulations
3 June 2026 - Ishaan Gupta has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) and 31 (5) of the SEBI (Substantial Acquisition of Shares and …
Annual reports
Concalls
-
Jun 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Oct 2024TranscriptAI SummaryPPT
-
Jun 2024TranscriptPPTREC
Business Overview:[1][2]
MOL specializes in manufacturing and distributing tablets, capsules, syrups, and ointments. It offers B2B contract and third-party manufacturing services for pharma companies in India and globally. Its portfolio includes generic and branded formulations, catering to government sectors, private institutions, and prominent pharma firms. Products are marketed via third-party distributors and loan licensing agreements.